Geron Corporation (GERN)

3.9300 -0.2100 (-5.07%) 收市：04:00PM EDT

Geron Corporation

919 East Hillsdale Boulevard
Suite 250
Foster City, CA 94404
United States
650 473 7700
https://www.geron.com

版塊: Healthcare
行業: Biotechnology
全職員工: 141

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. John A. Scarlett M.D.	Chairman of the Board, President & CEO	1.36M	無	1951
Ms. Michelle J. Robertson	Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer	340.98k	無	1967
Dr. Andrew J. Grethlein Ph.D.	Executive VP & COO	827.01k	無	1964
Mr. Scott Samuels	Executive VP, Chief Legal Officer & Corporate Secretary	485.32k	無	無
Ms. Aron Feingold	Vice President of Investor Relations & Corporate Communications	無	無	無
Ms. Shannon Odam	Senior VP & Chief People Officer	無	無	1975
Ms. Melissa A. Kelly Behrs	Executive VP of Business Operations & Chief Alliance Officer	753.22k	無	1964
Mr. Anil Kapur	Executive VP of Corporate Strategy & Chief Commercial Officer	654.89k	無	1970
Mr. Edward E. Koval	Executive VP & Chief Business Officer	無	無	1962
Dr. Faye Feller M.D.	Executive VP & Chief Medical Officer	無	無	1983

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

公司管治

截至 2024年4月29日 止，Geron Corporation 的 ISS 管治質素評分為 6。 Pillar 分數正在審核中：8；董事會：5；股東權利：7；現金賠償：6。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。